MAP-IDM: Identification of Molecular Markers of Sudden Death at the Acute Phase of Myocardial Infarction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1011 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-12-31

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We propose a comparative case-control study on the 2 following groups of patients:

* Cases: 500 patients with ventricular fibrillation at the acute phase of myocardial infarct,
* Controls: 500 patients without ventricular fibrillation at the acute phase of myocardial infarct.

The primary endpoint in this study is the correlation phenotype/genotype of sudden death at the acute phase of myocardial infarct.

The first phase of the study, including patients' recruitment, clinical and biological data collection, will last 82 months. The second phase will concern the genotype/phenotype analysis and the identification of polymorphisms associated with a sudden death risk after a myocardial infarction.

This study will allow a better knowledge of the mechanisms of sudden death and the identification of new risk markers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Molecular Epidemiology of Myocardial Infarction and Stroke in Older Adults - Ancillary to CHS

NCT00078429

Coronary Disease Cardiovascular Diseases Heart Diseases +2 more

COMPLETED

Genetic Epidemiology of CVD Risk Factors

NCT00053521

Cardiovascular Diseases Heart Diseases

COMPLETED

Genetic Autopsy and Sudden Death

NCT02920203

Sudden Death

UNKNOWN

Epidemiology of Cardiovascular Diseases in The Elderly

NCT00005186

Cardiovascular Diseases Heart Diseases

COMPLETED

Utility of the SomaLogic Cardiovascular Disease (CVD) Secondary Risk Panel for Cardiovascular Risk

NCT03599531

Cardiovascular Risk Factor Cardiovascular Diseases

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The number of sudden death is estimated around 50000 in France. In most cases, these deaths are due to myocardial infarction. This complication occurs, for 70% of cases, at the patient's residence, within 30 minutes following the thoracic pain. Emergency care often comes too late and allows only 2% of the patients having a heart failure to be revitalized.

At equal sex, age and clinical status, patients may or not develop ventricular rhythm disorders. Then, the notions of risk background and genetic disposition should be investigated.

No prospective study has been conducted on a sufficient number of patients yet. Such a study and the recent development of new genetic technologies will help identifying markers of sudden death risk at the acute phase of myocardial infarction.

The study we are implementing will increase knowledge on sudden death mechanisms at the acute phase of myocardial infarction. The analysis of phenotypic/genotypic relations will lead to an identification of new risk markers. Further evaluations of new diagnostic and therapeutic strategies will be possible on the basis of this trial.

Ventricular fibrillation at the acute phase of myocardial infarction follows a polygenic determinism. The genes involved in this electrical trouble are those which lead to the expression of potassic, calcic and sodic channels of ventricular myocytes: KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, PRKAG2, RyR2, PKP2, DSP, CASQ2, CACNA1C, and FKBP1B.

An association of a favourable genetic background and ischemia represents a cause for ventricular arrhythmia as a complication of myocardial infarction.

Haplotypes or genes considered as new markers for sudden death risk of ischemic origin will be searched.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

500 patients with ventricular fibrillation at the acute phase of myocardial infarct

Blood sample

Intervention Type GENETIC

Blood sample Determination of genetic background

2

500 patients without ventricular fibrillation at the acute phase of myocardial infarct.

Blood sample

Intervention Type GENETIC

Blood sample Determination of genetic background

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sample

Blood sample Determination of genetic background

Intervention Type GENETIC

Blood sample

Blood sample Determination of genetic background

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients admitted to ICU for MI and presenting the following criteria:
* Age \> 18
* Group 1 (Case) Patients with cardiac arrest and ventricular fibrillation developed up to 24 h post MI Group 2 (control) Patients with MI (no ventricular fibrillation)
* Written informed consent.